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Osteoporosis is a common disease that affects the majority of older women and
men. The pathophysioloy of osteoporosis involves a broad spectrum of endogenous
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Purpose: Genetic factor is an important predisposing element influencing the
susceptibility to osteoporosis and related complications. The purpose of the
present study is to investigate whether genetic polymorphisms of farnesyl
diphosphate synthase (FDPS) or geranylgeranyl diphosphate synthase (GGPS)
genes were associated with the response to bisphosphonate therapy. Materials
and Methods: In the present study, 144 Korean women with osteoporosis were
included. Among 13 genetic polymorphisms found within the FDPS and GGPS1
gene, 4 genetic polymorphisms with frequencies > 5% were selected for further
study. Bone mineral density (BMD) response after 1 year treatment of
bisphosphonate therapy was analyzed according to the genotypes. Results:
Women with 2 deletion allele of GGPS1 -8188A ins/del (rs3840452) had
significantly higher femoral neck BMD at baseline compared with those with
one or no deletion allele (0.768 ± 0.127 vs. 0.695 ± 0.090 respectively; p =
0.041). The response rate of women with 2 deletion allele of GGPS1 -8188A
ins/del (28.6%) was significantly lower than the rate of women with one (81.4%)
or no deletion allele (75.0%) (p = 0.011). Women with 2 deletion allele of
GGPS1 -8188A ins/del had 7-fold higher risk of non-response to bisphosphonate
therapy compared with women with other genotypes in GGPS1 -8188 after
adjusting for baseline BMD (OR = 7.48; 95% CI = 1.32-42.30; p = 0.023). Other
polymorphisms in FDPS or GGPS1 were not associated with lumbar spine
BMD or femoral neck BMD. Conclusion: Our study suggested that GGPS1 -
8188A ins/del polymorphism may confer susceptibility to femoral neck BMD
response to bisphosphonate therapy in Korean women. However, further study
should be done to confirm the results in a larger population. 
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INTRODUCTIONand environmental factors. At any particular age, about
70% of the bone phenotype variance is explained by
genetic factors.
1 Although no single major determinant has
been established, polymorphisms in vitamin D receptor
gene,
2 collagen type I alpha 1 gene,
3,4 estrogen receptor
gene,
5 interleukin-1 receptor antagonist gene,
6 interleukin-6
gene,
7 transforming growth factor receptor gene,
8 transfor-
ming growth factor beta 1 gene,
9 insulin-like growth
factor-1 pathway,
10 calcitonin receptor gene,
11 apolipopro-
tein E gene
12 and chromosomal loci 11q 12-13
13 have been
shown to be associated with bone mineral density (BMD).
Recent clinical trials have shown that response rates to
bisphosphonate therapy, range from approximately 70% to
75% based on changes in BMD.
14,15 Although bisphospho-
nate is known as a potent inhibitor of bone resorption and
used for the treatment and prevention of osteoporosis, non-
responders to bisphosphonate therapy is of potential concern
to clinicians and patients.
16 Several studies have been
conducted to identify high risk groups of non-responder(s),
based on baseline characteristics,
14 early changes in bioche-
mical markers of bone turnover
17 and early changes in
BMD.
18 However, little is known about the common charac-
teristics of non-responder(s) to help clinicians decide whether
to initiate bisphosphonates or not. Variability in therapeutic
response may reflect complex genetic factors. Indeed,
several lines of evidence demonstrated that genetic factors
were associated with response of treatment with bisphos-
phonate. For instance, Qureshi, et al.
19 have identified
signi-ficant associations between genetic polymorphisms
of collagen type I alpha 1 gene and BMD response to
alendro-nate treatment. In addition, femoral neck BMD
response to cyclic etidronate therapy has been shown to be
associated with vitamin D receptor gene polymorphism.
20,21
Farnesyl diphosphate synthase (FDPS) and geranyl-
geranyl diphosphate synthase (GGPS) belong to the target
enzymes in isoprenoid biosynthesis pathway, which are
inhibited by bisphosphonate. Treatment with bisphos-
phonate results in reduction of geranylgeranyl diphosphate
levels and induction of osteoclast apoptosis.
22,23 Based on
these, we hypothesized that genetic polymorphisms of
FDPS and GGPS are good candidate for variable responses
of BMD to bisphosphonate treatment. We, therefore, under-
took this study to examine whether genetic polymorphisms
of FDPS and GGPS1 were associated with response rate to
bisphosphonate treatment among Korean women with
osteoporosis.
Subjects
The study group comprised pre- and post-menopausal
women with newly diagnosed osteoporosis, who were
given treatment with bisphosphonate therapy for the first
time, and were admitted to two teaching hospitals located
in Korea (Seoul National University Hospital and Ajou
University Hospital) between September 1998 and January
2005. Clinical, laboratory and radiological studies were
performed to exclude secondary causes of osteoporosis,
such as hypogonadism, hyperthyroidism, multiple myeloma,
and endogenous or exogenous hypercortisolism. Diagnosis
of osteoporosis was made using manufacturer-provided
reference values for Koreans and World Health Organiza-
tion T-score criteria (T-score ≤ -2.5 at any site). Among
total 182 patients, 38 patients dropped out during study
period and 144 patients were finally analyzed, based on
per protocol. The study was approved by the committee on
human research of Seoul National University Hospital and
written informed consent from all subjects was obtained at
the time of blood sampling. 
Treatment and diagnosis
All women received alendronate (Fosamax, Merck Sharp)
at a dose of 10 mg/day or risedronate (Actonel, Sanofi-
aventis) at a dose of 5 mg/day. Patients were instructed to
take the medication orally in the morning at least 30 min
before breakfast with abundant water and on an empty
stomach after an overnight fast, and to remain upright for
at least 30 min after dosing. All patients were supple-
mented with calcium (200-600 mg elementary calcium per
day) and vitamin D (200-800 IU per day).
BMD (g/cm
2) of lumbar spine and femoral neck was
measured at baseline by dual energy X-ray absorptiometry
(DXA) using Lunar Prodigy Densitometer or Lunar Ex-
pert-XL densitometer (GE Medical. Systems, Madison,
WI, USA). After 12 months of treatment, participants were
followed up for BMD measurements.
Genotyping
From all subjects, 10 mL of peripheral blood was obtained.
The genomic DNA was extracted from peripheral blood
samples with using a PUREGENE blood DNA kit (Gentra
Inc. Minneapolis, MN, USA) following the manufacturer’s
protocol. 
For the SNP discovery, we screened for genetic variations
in the FDPS and GGPS1 gene, including 2kb promoter
region, using direct sequencing of 24 control samples and
sequences were analyzed using an Applied Biosystems
(Foster City, CA, USA) 3730xl DNA Analyzer. All SNPs
and sequence alignments were analyzed by the Polyphred
5.04 (University of Washington, Seattle, WA, USA; http://
droog.mbt.washington.edu/PolyPhred.html). Then, to in-
vestigate common polymorphisms, 4 single nucleotide
polymorphisms with frequencies > 5% were selected among
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MATERIALS AND METHODS the 13 polymorphisms (Table 1). 
The FDPS gene polymorphisms were determined by
SNP-ITTM assays with the SNPstream 25KTM System
(Orchid Biosciences, Princeton, NJ, USA). Briefly, the
genoemic DNA region spanning the polymorphic site was
amplified using one each of phosphotiolated primer and
regular PCR primer (Table 2). The genotypes of GGPS1
gene were assayed by single base primer extension assay
by using an ABI PRISM SNaPShot Multiplex kit and ABI
Prism 3730xl DNA analyzer (ABI, Foster City, CA, USA)
according to the manufacturer’s recommendation. 
Statistical analysis
Genotype distributions were tested for Hardy-Weinberg
equilibrium using χ 2 analysis. Difference in variables bet-
ween responders and non-responders were tested using t-
test for independent samples. Differences in continuous
variables were assessed by linear regression analyses with
or without adjusting for baseline BMD. Age and body
mass index (BMI) were tested as covariates in the model,
however, the association between genetic polymorphisms
and BMD were not significantly changed. Therefore, they
were omitted in the final model for statistical stability.
Results are presented as mean ± standard deviation (SD).
A pvalue of < 0.05 was considered statistically significant. 
Non-responder(s) to treatment were defined as subjects
who experienced any decrease in first one year following
BMD measurements. Non-responders in respect of lumbar
spine BMD or femoral neck were analyzed separately.
Association between response rate and genotype was cal-
culated using Fisher’s exact test. The risk of non-response to
treatment was estimated with odds ratios (ORs) and 95%
GGSP1 Polymorphism and Response to Bisphosphonate
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Table 1.Results of Discovery of Genetic Polymorphisms among 48 Control Samples
Gene  rs number Location Genotype Frequency (n = 48)
FDPS rs2297480* Promoter -99 C / A C : A = 0.766 : 0.234
FDPS rs16836819 Exon2 Asn68Asn C : T = 0.989 : 0.011
FDPS DL1000995 Intron5 IVS5 + 86G / C G : C = 0.99 : 0.01
FDPS DL1000990 Intron6 IVS6 + 42C / T C : T = 0.99 : 0.01
FDPS rs11264361* Intron8 IVS8 + 66G / T G : T = 0.793 : 0.207
GGPS1 rs3840452* Promoter -8188T ins / del Ins : del = 0.67 : 0.33
GGPS1 DL1001049 Promoter -7908C ins / del Ins : del = 0.99 : 0.01
GGPS1 DL1001050 Promoter -6757G / ins[G] G : Ins[G] = 0.969 : 0.031
GGPS1 DL1001051 Exon1 (5’UTR)  -6677C / T C : T = 0.969 : 0.031
GGPS1 DL1000992 Intron2 IVS2 + 23T / C T : C = 0.979 : 0.021
GGPS1 DL1000993 Intron2 IVS2 + 114T / C T : G = 0.989 : 0.011
GGPS1 DL1000994 Intron2 IVS2 + 404A / G A : G = 0.969 : 0.031
GGPS1 rs3841735* Intron3 IVS3 - 13A del / ins Del : Ins = 0.75 : 0.25
DL number represents Korean specific SNP. 
*Selected SNPs for further analysis.
Table 2.Primer Sequence for PCR and SNP-ITTM assay and / or SNaPShot
Gene rs number Primer Sequence(5’ - 3’)
PCR forward TAATTGTCCCCAAGCACATT
FDPS rs2297480 PCR reverse AAAGGCAGAGGCATGGTG
Genotyping AGGGAGGGGCACTCTGGGCTAAGGC
PCR forward TAGCAGAGAACAGGCACCA
FDPS rs11264361 PCR reverse AAAGAGGTCAAGGTAATCATCCT
Genotyping TTCACTCCTCCTCTGCCCAGGAACC
PCR forward AAGTCACCAAACACACCTTCCT
GGPS1 rs3840452 PCR reverse CTCGGCCCTCACGTTGT
Genotyping TTCGGGGGCTGGCGCCTGGT
PCR forward AGCTCTGCAGTAGGTAATGG
GGPS1 rs3841735 PCR reverse TCTTCTTCAGTGGGACAAGT
Genotyping AATAAGTGAAATTTTCAATTTTTTTconfidence intervals (95% CIs), using logistic regression
models adjusting for baseline BMD. Statistical analyses
were performed using SPSS 12.0 (SPSS Inc., Chicago, IL,
USA).
General characteristics and results of measurements of the
144 participants are shown in Table 3. The average age,
height, weight and BMI were 61.5 ± 9.9 yrs, 153.6 ± 5.6
cm, 55.5 ± 8.6 kg, and 23.5 ± 3.3 kg/m
2, respectively. The
average baseline and 1 year follow-up BMD of lumbar
spine were 0.789 ± 0.122 g/cm
2 and 0.839 ± 0.126 g/cm
2,
respectively. The average percent change of lumbar spine
was 6.7 ± 7.0%. The average baseline and 1 year follow-
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RESULTS
Table 3.Characteristics of Study Subjects before and after 
12 Months of Treatment with Bisphophonate (n = 144)
Characteristics Mean ± SD
Age (yrs) 61.5 ± 9.9
Height (cm) 153.6 ± 5.6
Weight (kg) 55.5 ± 8.6
BMI (kg/m
2) 23.5 ± 3.3
Lumbar spine BMD 
Baseline BMD (g/cm
2) 0.789 ± 0.122
Follow-up BMD (g/cm
2) 0.839 ± 0.126
Percent change (%) 6.7 ± 7.0
Femoral neck BMD
Baseline BMD (g/cm
2) 0.698 ± 0.093
Follow-up BMD (g/cm
2) 0.724 ± 0.097
Percent change (%) 3.7 ± 7.2
BMD, bone mineral density.
Table 4. Association between FDPS and GGPS1 Genetic Polymorphisms and Bone Mineral Density (BMD) before and after 
12 months of Treatment with Bisphosphonate (10 mg/day) (mean ± SD)
Gene
rs number and Genotype
pvalues*
position Major homozygous Heterozygous Minor homozygous
FDPS rs2297480 Number 87 46 7
-99C / A Lumbar Baseline 0.788 ± 0.120 0.784 ± 0.132 0.821 ± 0.129 0.473
Follow-up 0.840 ± 0.117 0.833 ± 0.145 0.887 ± 0.113 0.368
% change 7.0 ± 7.6 6.0 ± 5.5 8.9 ± 9.7 0.264
Femoral Baseline 0.696 ± 0.089 0.693 ± 0.095 0.730 ± 0.135 0.346
Follow-up 0.720 ± 0.094 0.718 ± 0.098 0.810 ± 0.133 0.060
% change 3.6 ± 6.4 3.4 ± 8.6 8.5 ± 10.0 0.059
FDPS rs11264361 Number 93 41 10
IVS8 + 66G / T Lumbar Baseline 0.787 ± 0.120 0.787 ± 0.132 0.812 ± 0.115 0.540
Follow-up 0.837 ± 0.119 0.839 ± 0.145 0.864 ± 0.116 0.825
% change 6.7 ± 7.5 6.5 ± 5.2 7.0 ± 8.8 0.724
Femoral Baseline 0.697 ± 0.089 0.694 ± 0.097 0.730 ± 0.112 0.268
Follow-up 0.718 ± 0.094 0.722 ± 0.099 0.790 ± 0.106 0.101
% change 3.4 ± 6.3 3.7 ± 8.8 6.7 ± 8.0 0.108
GGPS1 rs3840452 Number 80 57 7
-8188T ins / del Lumbar Baseline 0.793 ± 0.114 0.782 ± 0.141 0.791 ± 0.036 0.961
Follow-up 0.838 ± 0.115 0.844 ± 0.146 0.821 ± 0.029 0.299
% change 6.0 ± 6.7 8.1 ± 7.4 2.2 ± 2.2 0.101
Femoral Baseline 0.705 ± 0.091 0.681 ± 0.086 0.768 ± 0.127 0.041
Follow-up 0.736 ± 0.097 0.700 ± 0.092 0.771 ± 0.112 0.374
% change 3.2 ± 6.0 5.0 ± 8.9 0.8 ± 4.6 0.533
GGPS1 rs3841735 Number 80 52 8
IVS3-13A del / ins Lumbar Baseline 0.796 ± 0.128 0.777 ± 0.125 0.777 ± 0.051 0.805
Follow-up 0.842 ± 0.130 0.837 ± 0.131 0.814 ± 0.056 0.430
% change 6.1 ± 6.4 8.0 ± 7.7 3.4 ± 4.2 0.158
Femoral Baseline 0.706 ± 0.091 0.681 ± 0.094 0.708 ± 0.098 0.732
Follow-up 0.738 ± 0.100 0.701 ± 0.091 0.717 ± 0.099 0.329
% change 3.4 ± 6.0 5.1 ± 9.4 1.3 ± 4.4 0.372
BMD, bone mineral density.
*pvalues were calculated by linear regression analysis (recessive model, major homozygous + heterozygous vs. minor homozygous); p-values of follow-up and 
% changes were adjusted for baseline BMD.up BMD of femoral neck were 0.698 ± 0.093 g/cm
2 and
0.724 ± 0.097 g/cm
2, respectively. The average percent
change of lumbar spine was 3.7 ± 7.2%. Responders at
lumbar spine BMD were older than non-responder(s) (62.5
± 9.8 vs. 55.6 ± 9.1; p < 0.05). At femoral neck, the age
between responders and non-responder(s) was not signifi-
cantly different. There were no significant differences in
the height, weight and BMI between responders and non-
responder(s), at lumbar spine and femoral neck.
All genotype frequencies of FDPS and GGPS1 were in
Hardy-Weinberg equilibrium. For FDPS rs2297480, FDPS
rs11264361, GGPS1 rs3840452 and GGPS1 rs3841735,
Hardy-Weinberg equilibrium χ 2 (p-value) were 0.08 (0.96),
3.12 (0.21), 0.62 (0.73) and 0.01 (0.99), respectively. Height
and weight were significantly associated with the genetic
polymorphisms of FDPS and GGPS1. Women with FDPS
AA genotype (rs2297480) or TT genotypes (rs11264361)
had higher weight than women with other genotypes (p <
0.01). Women with GGPS1 -8188A two del alleles
(rs3840452) had higher height than women with other
genotypes (p = 0.017) (data not shown). Associations bet-
ween BMD and genetic polymorphisms of GGPS1 and
FDPS are shown in Table 4. Participants with two deletion
allele of GGPS1 -8188A ins/del had significantly higher
baseline femoral neck BMD than those with one or no
deletion allele (0.768 ± 0.127 vs 0.695 ± 0.090; p = 0.041
recessive model). This association remained significant after
adjusting for age and BMI (p = 0.018), but not significant
after adjustment for either height or weight (data not shown). 
Based on the response criteria at femoral neck BMD, the
GGSP1 Polymorphism and Response to Bisphosphonate
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Table 5. Association between FDPS and GGPS1 Genetic Polymorphisms and Treatment Response with Bisphosphonate 
after 12 Months Follow Up 
Non-responder Responder Response
Recessive
Variant Gene / Locus Genotype
n (%) n (%) rate (%)
Model
OR* (95% CI)
Lumbar spine BMD
rs2297480 FDPS CC 14 (70) 71 (60) 83.5 0.90 
-99 CA 5 (25) 41 (35) 89.1 (0.10 - 8.01)
AA 1 (5.0) 6 (5.1) 85.7 p= 0.926
rs11264361 FDPS GG 15 (71) 77 (64) 83.7 1.42 
IVS8 + 66 GT 4 (19) 36 (30) 90.0 (0.28 - 7.27)
TT 2 (9.5) 8 (6.6) 80.0 p= 0.671
rs3840452 GGPS1 Ins / Ins 16 (76) 64 (53) 80.0 1.18
-8188A Ins / Del 4 (19) 52 (43) 92.9 (0.13 - 10.66)
Del / Del 1 (4.8) 5 (4.1) 83.3 p= 0.883
rs3841735 GGPS1 Del / Del 14 (70) 66 (56) 82.5 1.02
IVS3 - 13T Del / Ins 5 (25) 46 (39) 90.2 (0.12 - 9.02)
Ins / Ins 1 (5.0) 6 (5.1) 85.7 p= 0.983
Femoral neck BMD
rs2297480 FDPS CC 16 (57) 50 (63) 75.8 N / A
-99 CA 12 (43) 24 (30) 66.7
AA 0 (0) 5 (6) 100
rs11264361 FDPS GG 17 (61) 52 (63) 75.4 N / A
IVS8 + 66 GT 11 (39) 22 (27) 66.7
TT 0 (0) 8 (9.8) 100
rs3840452 GGPS1 Ins / Ins 15 (54) 45 (55) 75.0 7.48
-8188A Ins / Del 8 (29) 35 (43) 81.4 (1.32 - 42.30)
Del / Del 5 (18) 2 (2) 28.6 p= 0.023
rs3841735 GGPS1 Del / Del 15 (56) 46 (58) 75.4 4.41
IVS3 - 13T Del / Ins 8 (30) 30 (38) 78.9 (0.89 - 21.79)
Ins / Ins 4 (15) 3 (3.8) 42.9 p= 0.068
BMD, bone mineral density.
*ORs were calculated by logistic regression model (recessive model, major homozygous + heterozygous vs. minor homozygous) adjusting for baseline BMD. 
Nonresponders to treatment was defined as subjects who have any decrease in the 1 year following BMD measurements. N / A, not applicable.response rate of women with two deletion allele of GGPS1
-8188A ins/del (28.6%) was significantly lower than the
rate of women with one deletion allele (81.4%) or subjects
with no deletion allele (75.0%) (p = 0.011) (Table 5).
Women with two deletion allele of GGPS1 -8188A ins/del
had 7-fold higher risk of non-response to bisphosphonate
therapy compared with women with other genotypes in
GGPS1 -8188 (OR = 7.48; 95% CI = 1.32-42.30; p= 0.023)
after adjusting for baseline BMD. This association between
GGPS1 -8188A ins/del and response rate remained signifi-
cant after adjusting for a covariate (age, height, weight or
BMI) or adjusting for multiple covariates (baseline BMD,
age and BMI) (p < 0.05). The sensitivity of GGPS1 -
8188A ins/del polymorphism genotyping for predicting
responder at the femoral neck for the “ins/ins” or “ins/del”
genotype was 97.6% (80/82) with a specificity of 17.9%
(5/28), and a positive predictive value of 77.7% (80/103). 
Analyses with additive or dominant models did not
show significant results. Other polymorphisms in FDPS or
GGPS1 were not associated with either baseline BMD or
response to treatment.
We found five and eight genetic polymorphisms of FDPS
and GGPS1, respectively, in Korean women and investi-
gated whether the genetic factors were associated with
BMD as well as the response to bisphosphonate treatment.
Among Korean women, GGPS1 -8188A ins/del genetic
polymorphism was associated with BMD at baseline and
the response rate to bisphosphonate therapy at femoral
neck. 
FDPS and GGPS are important enzymes in the isopre-
noid biosynthesis pathway, which is important target of
bisphosphonate treatment. In this study, we were not able
to provide mechanistic insight into the functional conse-
quences of the GGPS1 -8188A ins/del polymorphism.
However, since GGPS1 -8188A ins/del polymorphism is
located at the promoter region of GGPS1 gene, it may be
plausible to expect that the polymorphism could alter
GGPS1 gene transcription level and alter the GGPS con-
centration in turn. The efficacy of bisphosphonate to
induce apoptosis of osteoclasts could be changed when
GGPS concentration changes, since GGPS is one of the
target molecules for bisphosphonate treatment.
23
Even though the association between GGPS1 -8188A
ins/del and response rate was significant after adjusting for
covariates (baseline BMD, age and BMI), there could be
other influence or confounding factors. Due to the study
design and limitation to obtain patient information, further
analyses including other phenotypes or lifestyle factors
such as serum bone turnover markers, vitamin D status,
PTH level, fracture history, smoking or alcohol history,
dietary characteristics, or compliance to medication were
not feasible. Future study including these factors could
enhance the knowledge regarding the pharmacogenetic
effect of FDPS and GGPS1 polymorphisms on bisphos-
phonate therapy. In addition, given that multiple compari-
son testing was performed in small number of participants,
this study may have high risk of type I error (false positive).
GGPS1 -8188A ins/del was significantly associated with
response rate at femoral neck, but not at lumbar spine.
Similar to the result at femoral neck, the response rate of
subjects with rare homozygote (del/del) at lumbar spine
(83.3%) was also lower than that of subject with common
homozygote (ins/ins) or heterozygote (ins/del) (85.3%),
although not statistically significant. Small sample size
might be the cause of insignificant statistical result regard-
ing lumbar spine. The effect of this polymorphism on
cortical bone and trabecular bone might be different, as
many previous studies have suggested that cortical bone
and trabecular bone have different drug effect and different
regulating genes.
24,25 Further study with larger sample size
and mechanism analyses could clarify this issue.
No gene-dose effect was found regarding the association
between GGPS1 -8188A ins/del and response rate at fe-
moral neck. This lack of gene-dose effect could result from
mechanism by which this polymorphism influences the
bisphosphonate response. Since the GGPS1 gene encodes
an enzyme, haploinsufficiency might not have enough
effect to alter the response rate. Further study regarding the
GGPS enzyme activity and the substrate levels would
reveal the mechanism.
GGPS1 -8188A ins/del was significantly associated with
response rate at femoral neck and baseline femoral neck
BMD, but no significant difference was found in the %
change in BMD at femoral neck. In accordance with the
response rate, the % change in BMD at femoral neck of
subject with two del allele was lower than that of subject
with one or no del allele, although not statistically signi-
ficant. This might also be due to small sample size, and
further studies with larger sample size are needed for the
verification.
The baseline BMD of subject with two del allele of
GGPS1 -8188A ins/del polymorphism was significantly
higher than those with one or no deletion allele. However,
this association was not significant when height was inclu-
ded as a covariate. And GGPS1 -8188A ins/del polymor-
phism was significantly associated with height. Also,
FDPS polymorphisms were significantly associated with
weight. Since isoprenoid biosynthesis pathway including
FDPS and GGPS enzyme is essential in the steroid syn-
thesis, genetic difference in FDPS or GGPS gene could
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DISCUSSIONalter the height and weight. However this association re-
garding height and weight is beyond the scope of present
study and further study is needed to investigate this issue.
Since the effect of bisphosphonate appears slowly in the
course of treatment, more than two years follow-up BMD
data could be adequate enough to determine a true response
rate to bisphosphonate. However, a well designed study to
predict subsequent BMD response to bisphosphonate from
early BMD response suggested that any improvement in
BMD at 6 or 12 months is strongly indicative of subsequent
BMD response.
18 Therefore, we assumed that one year
follow-up BMD would be sufficient to classify “non-res-
ponder(s)” and “responders”.
In the present study, we used “0%” (any decrease in
BMD) as a cut-off value for identifying “non-responder(s)”,
consistent with previous studies.
15,19 Other investigators
also used “3% increase” as a cut-off value for significant
BMD increase (least significant change) due to innate
precision error of the test,
14,26 and suggested that a “0-3%
increase” should be considered as an “indeterminable
response” rather than a significant response”. We chose
0% as our cut-off value for two reasons. First, as the main
objective of the present study was to identify definite “non-
responder(s)” (any decrease in BMD) in the early course
of therapy, the use of 0% as a cut-off value would be more
reasonable to separate “indeterminable response” patients
(0-3% increase in BMD) from the definite “non-respon-
der(s)” (any decrease in BMD). Second, in light of the fact
that more than 1 year is often required for bisphosphonate
to sufficiently increase BMD by more than 3%, the use of
cut-off value of 3% would underestimate the response
rates in our short-term follow-up study design (1 year).
There are several limitations to the present study. Consi-
derably small sample size does limit the statistical power
of the present study. In particular, the number of subjects
with two del/del allele of GGPS1 -8188A ins/del polymor-
phism was too small to make a firm conclusion. Lack of
information regarding the risk factors for osteoporosis
(level of physical activity, serum bone turnover markers,
PTH level, fracture history, smoking or alcohol history,
dietary characteristics, or compliance to medication) is an
another important limitation to the present study. Other
limitations include multiple testing issue and lack of
biochemical results to support the underlying mechanisms.
Future studies with larger population and functional
mechanisms are needed and we are in a process to pursue
this project. 
In conclusion, our present study indicates that GGPS1
-8188A ins/del polymorphism is associated with the femoral
neck BMD response rate to bisphosphonate therapy, al-
though the strength of association was weak due to small
sample size. These results could be used to build a basis of
genotype-tailored guidelines for osteoporosis treatment,
such as genotype screening before initiation of bisphos-
phonate therapy to prevent potential “non-responder(s)”
from taking unnecessary medications.
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